gms | German Medical Science

72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

06.06. - 09.06.2021

A multi-omics approach to identify markers for glioblastoma recurrency

Ein Multi-Omics Ansatz zur Identifizierung von Markern für Glioblastom-Rezidive

Meeting Abstract

  • presenting/speaker Agnes Schäfer - Philipps-Universität Marburg, Klinik für Neurochirurgie, Marburg, Deutschland
  • Andreea-Cristina Benescu - Philipps-Universität Marburg, Klinik für Neurochirurgie, Marburg, Deutschland
  • Lara Evers - Philipps-Universität Marburg, Klinik für Neurochirurgie, Marburg, Deutschland
  • Lara Meier - Philipps-Universität Marburg, Klinik für Neurochirurgie, Marburg, Deutschland
  • Christopher Nimsky - Philipps-Universität Marburg, Klinik für Neurochirurgie, Marburg, Deutschland
  • presenting/speaker Jörg-Walter Bartsch - Philipps-Universität Marburg, Klinik für Neurochirurgie, Marburg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie. sine loco [digital], 06.-09.06.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocP053

doi: 10.3205/21dgnc341, urn:nbn:de:0183-21dgnc3413

Veröffentlicht: 4. Juni 2021

© 2021 Schäfer et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Knowledge of individual time-to-recurrence (TTR) of GBM patients is critical to enable life-prolonging repeated surgery. MicroRNAs (miRNAs) are non-coding single-stranded RNA molecules of 21 to 25 nucleotides and related to numerous tumor cell functions in GBM. Extracellular vesicles (EVs) are small, stable, membrane-closed particles secreted by tumor cells. EVs encapsulate various tumor-specific molecules such as miRNAs and contribute to GBM progression. We envisage realization of a multi-omics approach integrating miRNAs, EVs and proteomics to enable a combined rational detection of markers associated with GBM recurrence.

Methods: Pre- and postoperative serum samples from newly diagnosed GBM patients and patients with GBM recurrencies were subjected in parallel to proteomic and radiomic analysis in conjunction with RNASeq analysis. EVs were separated from serum samples via differential high-speed centrifugation. Isolation of miRNA was performed using the total exosome RNA and protein isolation kit and miRNA from cells and tissues were isolated using the miRNeasy tissue/cells advanced mini kit. Micro RNAs were detected using qPCR. Osteopontin protein levels were determined by ELISA.

Results: 238 different miRNAs were identified in a first setup of 10 patients (GBM WHO°IV, IDH WT) by RNASeq analysis. Interestingly, some particular miRNAs were identified as significantly expressed in overlapping groups comparing serum, EDTA and serum-EV samples (p-value >0.05, FC-2.0). Initially, we identified four candidate miRNAs (miR-19a-3p, miR-29b-3p, miR-130a-3p and miR-181a-5p) with functional relevance in GBM. In particular, miR-181a-5p is correlated to several genes and is linked to improved survival and decreased recurrence in GBM. Its expression levels positively correlate with those of MMP9 (n=21, p=0.01, r2= 0.3) and MMP14 (n=19, p=0.04, r2= 0.22) in GBM tissue samples. Osteopontin (OPN) protein, a potent inducer of tumor angiogenesis was also correlated with different miRNA expression levels and high levels of OPN in preoperative EDTA samples (ELISA) are linked with poor prognosis (Kaplan-Meier-Curve, n=12).

Conclusion: This study demonstrates, although with a limited number of GBM patients analysed so far, that a combination of serum markers could potentially be used to monitor GBM progress and identify recurrence at an early stage in disease progression. In particular, the combination of miRNA and proteins isolated from serum EVs have a high potential to be considered as specific.